Bernards René
Division of Molecular Carcinogenesis and Center for Biomedical Genetics, The Netherlands Cancer Institute, Plesmanlaan 121,1066, CX Amsterdam, The Netherlands.
Cancer Cell. 2005 Jun;7(6):503-4. doi: 10.1016/j.ccr.2005.05.020.
The success of the family of kinases as targets for small-molecule cancer therapeutics is probably best illustrated by the efficacy of the drug Gleevec. In spite of this, the function of many of the kinases in the mammalian genome remains unknown. In a recent paper, MacKeigan and colleagues report a functional genetic screen using RNA interference to identify kinases and phosphatases involved in programmed cell death (MacKeigan et al., 2005). Functional annotation is a prerequisite for selection of new drug targets. Such studies may therefore lay the foundation for the next generation of cancer drugs.
激酶家族作为小分子癌症治疗靶点的成功，或许通过药物格列卫的疗效得到了最佳体现。尽管如此，哺乳动物基因组中许多激酶的功能仍不为人知。在最近一篇论文中，麦凯根及其同事报告了一项利用RNA干扰进行的功能基因筛选，以识别参与程序性细胞死亡的激酶和磷酸酶（麦凯根等人，2005年）。功能注释是选择新药物靶点的先决条件。因此，此类研究可能为下一代癌症药物奠定基础。
